ArticleCureus2026
Early Psychiatric Manifestations of Lafora Disease: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lafora disease is a rare genetic progressive myoclonic epilepsy characterized by the onset of epileptic seizures and myoclonus during adolescence, followed by a rapid progression toward neurodegeneration. However, an often underrecognized aspect of this condition is the presence of psychiatric manifestations, particularly depressive and psychotic disorders, which may emerge prior to or concurrently with the neurological symptoms. We report the case of a 39-year-old woman with biopsy-confirmed Lafora disease whose psychiatric symptoms preceded the onset of neurological manifestations by several years. Between the ages of 12 and 16 years, she presented with recurrent suicidal behavior, episodes of wandering, severe depressive symptoms, and psychotic manifestations, including auditory and visual hallucinations, persecutory delusions, and behavioral disturbances, initially leading to psychiatric diagnoses and treatment. Neurological symptoms appeared later at the age of 20 years, with visual hallucinations followed by generalized tonic-clonic seizures, progressive myoclonus, and cognitive decline. The diagnosis of Lafora disease was ultimately confirmed by axillary skin biopsy, demonstrating periodic acid-Schiff (PAS)-positive Lafora bodies. This case highlights the importance of a detailed investigation into the early presentation and longitudinal evolution of these psychiatric manifestations in order to distinguish them from primary psychiatric disorders and to consider them as potential clinical clues that may precede the neurological manifestations of Lafora disease. Recognition of these manifestations may facilitate consideration of an earlier diagnosis of Lafora disease and help reduce diagnostic delay in adolescents presenting with atypical psychiatric symptoms. Furthermore, this work stresses the importance of structured interdisciplinary collaboration between neurologists and psychiatrists in the management of progressive myoclonic epilepsies and the need to develop and implement standardized recommendations for psychiatric screening in at-risk adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.